References 1 Ferlay J et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359 – 86. 2 National Cancer Intelligence Network. Stage Breakdown by CCG 2014. London: NCIN; 2016. 3 Northern Ireland Cancer Registry, Queens University Belfast, Incidence by stage 2010 – 2014. Belfast: NICR; 2016. 4 Alexandrov LB et al. Signatures of mutational processes in human cancer. Nature 2013; 500:415 – 21. 5 Howlader N et al. SEER Cancer Statistics Review, 1975 – 2014, based on November 2016 SEER data submission. Bethesda, MD: National Cancer Institute; 2017. https:// seer. cancer. gov / csr / 1975 _ 2014 /( accessed May 2018). 6 Johnson DH, Schiller JH, Bunn PA Jr. Recent clinical advances in lung cancer management. J Clin Oncol 2014; 32:973 – 82. 7 Reck M et al. Management of non-small-cell lung cancer: recent developments. Lancet 2013; 382:709 – 19. 8 Forde PM, Ettinger DS. Targeted therapy for non-small-cell lung cancer: past, present and future. Expert Rev Anticancer Ther 2013; 13:745 – 8. 9 Ettinger DS. Ten years of progress in non-small cell lung cancer. J Natl Compr Canc Netw 2012; 10:292 – 5. 10 Swanton C, Govindan R. Clinical implications of genomic discoveries in lung cancer. N Engl J Med 2016; 374:1864 – 73. 11 Kris MG et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014; 311:1998 – 2006 12 Kwak EL et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363:1693 – 703. 13 Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014; 511:543 – 50. 14 Soda M et al. Identification of the transforming EML4-ALK fusion gene in non small cell lung cancer. Nature 2007; 448:561 – 6. 15 Takeuchi K et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 2008; 14:6618 – 24. 16 Hallberg B, Palmer RH. The role of the ALK receptor in cancer biology. Ann Oncol 2016; 27( Suppl 3): iii4 – iii15. 17 Choi YL et al. A novel fusion of TPR and ALK in lung adenocarcinoma. J Thorac Oncol 2014; 9:563 – 6. 18 Fang DD et al. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib. J Thorac Oncol 2014; 9:285 – 94. 19 Hong M et al. HIP1-ALK, a novel fusion protein identified in lung adenocarcinoma. J Thorac Oncol 2014; 9:419 – 22. 20 Cui S et al. Use of capturebased next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer. Oncotarget 2017; 8( 2): 2771 – 80. 21 Solomon BJ et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014; 371:2167 – 77. 22 Seto T. et al. CH5424802( RO5424802) for patients with ALK-rearranged advanced nonsmall-cell lung cancer( AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol |
2013; 14:590 – 8. 23 Peters S et al. Alectinib versus crizotinib in untreated ALK-positive non – small-cell lung cancer. N Engl J Med 2017; 377( 9): 829 – 38. 24 Iwama E et al Development of anaplastic lymphoma kinase( ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer. Onco Targets Ther 2014; 7:375 – 85. 25 Shaw AT, Kim DW, Nakagawa K. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368:2385 – 94. 26 Hunt J. Molecular pathology in anatomic pathology practice: a review of basic principles. Arch Pathol Lab Med 2007; 132( 2): 248 – 60. 27 Babic A et al. The impact of preanalytical processing on staining quality for H & E, dual hapten, dual color in situ hybridization and fluorescent in situ hybridization assays. Methods. 2010; 52( 4): 287 – 300. 28 Minca E et al. ALK status testing in nonsmall cell lung carcinoma: correlation between ultrasensitive IHC and FISH. J Mol Diagn 2013; 15( 3): 341 – 6. 29 Sholl L et al. Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. J Thorac Oncol 2013; 8( 3): 322 – 8. 30 Camidge DR et al. Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer. Implications for ALK inhibitor therapy. Cancer 2013; 119( 22): 3968 – 75. 31 Selinger C et al. Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 2013; 26( 12): 1545 – 53. 32 Conde E et al. Accurate identification of ALK positive lung carcinoma patients: novel FDAcleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry. PLoS One 2014; 9: e107200. 33 Ying J et al. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. Ann Oncol 2013; 24:2589 – 93. 34 Kim H et al. Discordance between anaplastic lymphoma kinase status in primary non-small-cell lung cancers and their corresponding metastases. Histopathology 2013; 62( 2): 305 – 14. 35 Salido M et al. Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J Thorac Oncol 2011; 6( 1): 21 – 7. 36 Yatabe Y. ALK FISH and IHC: you cannot have one without the other. J Thorac Oncol 2015; 10:548 – 50. 37 Savic S et al. Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended. Lung Cancer 2015; 89:104 – 9. 38 Leighl NB et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists / International Association for the |
study of lung cancer / association for molecular pathology guideline. J Clin Oncol 2014; 32:3673 – 9. 39 Cabillic F et al. Parallel FISH and immunohistochemical studies of ALK status in 3244 non-smallcell lung cancers reveal major discordances. J Thorac Oncol 2014; 9:295 – 306. 40 Ilie MI et al. Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK‘ borderline’- positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies. Ann Oncol 2015; 26:238 – 44. 41 Antonescu CR et al. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement. Am J Surg Pathol 2015; 39:957 – 67. 42 Roychowdhury S et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 2011; 3:111ra121. 43 Frampton GM et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013; 31:1023 – 31. 44 Kamps R et al. Next-generation sequencing in oncology: Genetic diagnosis, risk prediction and cancer classification. Int J Med Sci 2017; 18( 2): 308. 45 Wu K et al. Next-generation sequencing for lung cancer. Future Oncol 2013; 9:1323 – 36. 46 Demidova I et al. Detection of ALK rearrangements in 4002 Russian patients: The utility of different diagnostic approaches. Lung Cancer 2017; 103:17 – 23. 47 Li W et al. Combinational analysis of FISH and immunohistochemistry reveals rare genomic events in ALK fusion patterns in NSCLC that responds to crizotinib treatment. J Thorac Oncol 2017; 12:94 – 101. 48 Pekar-Zlotin M et al. Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer. Oncologist 2015; 20:316 – 22. 49 Ali SM et al. Comprehensive genomic profiling identifies a subset of crizotinibresponsive ALK-rearranged non-small cell lung cancer not detected by fluorescence in situ hybridization. Oncologist 2016; 6:762 – 70. 50 Pirazzoli V et al. Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1. Cell Rep 2014; 7:999 – 1008. 51 Coco S, Truini A, Vanni I. Next generation sequencing in non-small cell lung cancer: new avenues toward the personalized medicine. Curr Drug Targets 2015; 16:47 – 59. 52 Oxnard GR, Arcila ME, Sima CS. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 2011; 17:1616 – 22. 53 Choi YL, Soda M, Yamashita Y. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010; 363:1734 – 9. 54 Doebele RC, Pilling AB, Aisner DL. Mechanisms of resistance to crizotinib in patients with ALK |
gene rearranged non-small cell lung cancer. Clin Cancer Res 2012; 18:1472 – 82. 55 Sasaki T., Koivunen J., Ogino A. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 2011; 71:6051 – 60. 56 Ettinger DS et al. Non-small cell lung cancer, Version 6.2015. J Natl Compr Canc Network 2015; 13( 5): 515 – 24. 57 Lee CK et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: A meta-analysis. J Natl Cancer Inst 2013; 105: 595 – 605. 58 Lindeman N et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors. J Mol Diagn 2018; 20:129 – 59. 59 Bulman W, Saqi A, Powell CA. Acquisition and processing of endobronchial ultrasound-guided transbronchial needle aspiration specimens in the era of targeted lung cancer chemotherapy. Am J Respir Crit Care Med 2012; 185:606 – 11. 60 Jurado J et al. The efficacy of EBUS-guided transbronchial needle aspiration for molecular testing in lung adenocarcinoma. Ann Thorac Surg 2013; 96: 1196 – 202. 61 Sequist LV et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 2011; 22:2616 – 24. 62 Li T et al. Genotyping and genomic profiling of non-smallcell lung cancer: Implications for current and future therapies. J Clin Oncol 2013; 31:1039 – 49. 63 Endris V et al. Molecular diagnostic profiling of lung cancer specimens with a semiconductorbased massive parallel sequencing approach: feasibility, costs, and performance compared with conventional sequencing. J Mol Diagn 2013; 15:765e775. 64 Sorber L et al. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients. Lung Cancer 2017; 107:100 – 7. 65 Travis WD et al. Diagnosis of lung adenocarcinoma in resected specimens: implications of the 2011 International Association for the Study of Lung Cancer / American Thoracic Society / European Respiratory Society classification. Arch Pathol Lab Med 2013; 137:685 – 705. 66 National Lung Cancer Audit Report 2012 [ Internet ]. 2012. www. hqip. org. uk / assets / NCAPOP- Library / NCAPOP-2012-13 / Lung-Cancer-National-Audit- Report-pub-2012. pdf( accessed May 2018). 67 Rosen S. World Market for Cancer Diagnostics, 5th Edition. 2013. 68 Travis WD et al. International Association for the Study of Lung Cancer / American Thoracic Society / European Respiratory Society: International multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc 2011; 8:381 – 5. 69 Xu Set al. Circulating tumor DNA identified by targeted sequencing in advancedstage non-small cell lung cancer patients. Cancer Lett 2016; 370:324 – 31. 70 Ross K et al. The potential diagnostic power of circulating tumor cell analysis for |
non-small-cell lung cancer. Expert Rev Mol Diagn. 2015; 15:1605 – 29. 71 Lanman RB et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cellfree circulating tumor DNA. PLOS One 2015; 10( 10): e0140712. 72 Schwaederle M et al. Detection rate of actionable mutations in diverse cancers using a biopsy-free( blood) circulating tumor cell DNA assay. Oncotarget 2016; 7( 9): 9707 – 17. 73 Massard C et al. Highthroughput genomics and clinical outcome in hard-to-treat advanced cancers: Results of the MOSCATO 01 Trial. Cancer Discov. 2017; 7:586 – 95. 74 Dalton WB et al. Personalized medicine in the oncology clinic: Implementation and outcomes of the Johns Hopkins Molecular Tumor Board. JCO Precision Oncology 2017; 31 May [ Epub ahead of print ]. 75 Rogers T-M et al. Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer. Sci Rep 2017; 7:42259. 76 Letovanec I et al. Evaluation of NGS and RT-PCR methods for ALK rearrangement in European NSCLC patients: Results from the ETOP Lungscape Project. J Thorac Oncol 2018; 13( 3): 413 – 25. |
150 |
||||
HHE 2018 | hospitalhealthcare. com |